Neurostatus Systems AG
We are pleased to inform you that by beginning of August 2016 we have transferred all Neurostatus
activities to the Neurologic Clinic and Policlinic of the University Hospital Basel.
We would like to thank you for your continuous support and trust throughout the last 20 years.
For more information on this transition please download the Communiqué below.


Press release – Transfer of Ownership of Neurostatus Services and Tools to University Hospital Basel

Publication in Multiple Sclerosis Journal

Neurostatus e-Scoring increases EDSS consistency up to 99.7%

All News

Job offers

There are no open jobs at the moment.

Neurostatus Systems AG


Amato MP, Fratiglioni L, Groppi C, Siracusa G, Amaducci L. Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis. Arch Neurol. 1988;45(7):746‐8.

Andersson PB, Goodkin DE. Outcome measures in multiple sclerosis clinical trials. Baillieres Clin Neurol. 1997;6(3):409‐28.

Butzkueven H, Chapman J, Cristiano E, Grand'Maison F, Hoffmann M, Izquierdo G, Jolley D, Kappos L, Leist T, Pöhlau D, Rivera V, Trojano M, Verheul F, Malkowski JP. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler. 2006;12(6):76974.

Cohen JA, Reingold SC, Polman CH, Wolinsky JS; International Advisory Committee on Clinical Trials in Multiple Sclerosis. Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurol. 2012;11(5):46776.

Francis DA, Bain P, Swan AV, Hughes RA. An assessment of disability rating scales used in multiple sclerosis. Arch Neurol. 1991;48(3):299301.

Goodkin DE, Cookfair D, Wende K, Bourdette D, Pullicino P, Scherokman B, Whitham R. Interand intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative

Research Group. Neurology. 1992;42(4):85963.

Hobart J, Freeman J, Thompson A. Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain. 2000;123 ( Pt 5):102740.

Hobart J, Kalkers N, Barkhof F, Uitdehaag B, Polman C, Thompson A. Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite. Mult Scler. 2004;10(1):416.

Hyland M, Rudick RA. Challenges to clinical trials in multiple sclerosis: outcome measures in the era of diseasemodifying drugs. Curr Opin Neurol. 2011;24(3):25561. Review.

Kappos L. European Study Group on Interferon β‐1b in Secondary Progressive MS. Placebocontrolled multicentre randomised trial of interferon β‐1b in treatment of secondary progressive multiple sclerosis. Lancet. 1988; 352:14911497.

Kappos L. Immunsuppressive Therapie der multiplen Sklerose mit Cyclosporin A und Azathioprin. Langzeiteffekte, Risiken, kernspintomographische und immunologische Befunde. Springer, 1990.

Kappos L, LechnerScott J, Lienert C. Neurostatus Neurostatus training and documentation DVD for a standardized neurological examination and assessment of Kurtzke’s functional systems and Expanded Disability Status Scale for MS patients. 2002, 2007, Basel, Switzerland. Available at: Accessed March 30, 2015.

Kappos L, Patzold U, Dommasch D, Poser S, Haas J, Krauseneck P, Malin JP, Fierz W, von Graffenried B, Gugerli US. Cyclosporine vs azathioprine in the longterm treatment of MS results of the German multicenter study. Ann Neurol 1988;23:5663.

Kragt JJ, Thompson AJ, Montalban X, Tintoré M, Río J, Polman CH, Uitdehaag BM. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. Neurology. 2008;70(13 Pt 2):108491.

Kurtzke JF. A new scale for evaluating disability in multiple sclerosis. Neurology 1955;5:580–3.

Kurtzke JF. On the evaluation of disability in multiple sclerosis. Neurology 1961;11:686–94. 

Kurtzke JF. Further notes on disability evaluation in multiple sclerosis, with scale modifications. Neurology1965;15:654–61.

Kurtzke JF. Clinical manifestations of multiple sclerosis. Multiple sclerosis and other demyelinating diseases. In: VinkenPJ,Bruyn GW, editors. Handbook of clinical neurology,vol. 9. Amsterdam: NorthHolland;1970:161–216.

Kurtzke JF. Rating neurologic impairment in multiple sclerosis. An expanded disability status scale(EDSS). Neurology1983;33:1444–52.

Kurtzke JF. The Disability Status Scale for multiple sclerosis: Apologia pro DSS sua. Neurology 1989a;39:291–302.

Kurtzke JF. Origin of DSS: to present the plan. Mult Scler. 2007;13(1):1203.

Kurtzke JF. Historical and clinical perspectives of the Expanded Disability Status Scale. Neuroepidemiology 2008;31:1–9.

Kurtzke JF. On the origin of EDSS. Multiple Sclerosis and Related Disorders 2015; 4:95103.

Kuzma JW, Namerow NS, Tourtellotte WW, Sibley WA, Kurtzke JF, Rose AS, Dixon WJ. An assessment of the reliability of three methods used in evaluating the status of multiple sclerosis patients. J Chronic Dis. 1969;21(11):80314.

LechnerScott J, Kappos L, Hofman M, Polman CH, Ronner H, Montalban X, Tintore M, Frontoni M, Buttinelli C, Amato MP, Bartolozzi ML, Versavel M, Dahlke F, Kapp JF, Gibberd R. Can the Expanded Disability Status Scale be assessed by telephone? Mult Scler. 2003;9(2):1549.

MeyerMoock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol. 2014;14:58.

Montalban X, Tintoré M, Río J, Galán I, Codina A. Interobserver variability in the evaluation of functional systems and Kurzke expanded disability status scale in a multiple sclerosis patient. Rev Neurol. 1996;24(130):6302.

Noseworthy JH. Clinical scoring methods for multiple sclerosis. Ann Neurol. 1994;36 Suppl:S805.

Noseworthy JH, Vandervoort MK, Hopkins M, Ebers GC. A referendum on clinical trial research in multiple sclerosis: the opinion of the participants at the Jekyll Island workshop. Neurology. 1989;39(7):97781.

Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology. 1990;40(6):9715. 

Patzold U, Pocklington P. Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 19761980. Acta Neurol Scand. 1982; 65: 248266.

Patzold U, Weinrich W. Vorschlag einer neurologischen Befunddokumentation mittels Markierungsbeleg. Nervenarzt. 1975;46:550556.

Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E. Clinical outcomes assessment in multiple sclerosis. Ann Neurol. 1996;40(3):46979. Review. 

Rudick RA, Cutter G, Reingold S. The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials. Mult Scler. 2002;8(5):35965.

Rudick RA, Kappos L. Measuring disability in relapsingremitting MS. Neurology 2010; 75(4): 296297.

Sharrack B, Hughes RA. Clinical scales for multiple sclerosis. J Neurol Sci. 1996;135(1):19.

Sharrack B, Hughes RA, Soudain S, Dunn G. The psychometric properties of clinical rating scales used in multiple sclerosis. Brain. 1999;122 ( Pt1):14159.

VerdierTaillefer MH, Zuber M, LyonCaen O, Clanet M, Gout O, Louis C, Alpérovitch A. Observer disagreement in rating neurologic impairment in multiple sclerosis: facts and consequences. Eur Neurol. 1991;31(2):1179.

Whitaker JN, McFarland HF, Rudge P, Reingold SC. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler. 1995;1(1):3747.

Willoughby EW, Paty DW. Scales for rating impairment in multiple sclerosis: a critique. Neurology. 1988;38(11):17938.

Wingerchuk DM, Noseworthy JH, Weinshenker BG. Clinical outcome measures and rating scales in multiple sclerosis trials. Mayo Clin Proc. 1997;72(11):10709.